Informatie:
Fout:
ID
22752
Beschrijving
Amisulpride Augmentation Therapy for Clozapine-resistant Schizophrenic Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01105481
Link
https://clinicaltrials.gov/show/NCT01105481
Trefwoorden
Versies (1)
- 11-06-17 11-06-17 -
Geüploaded op
11 juni 2017
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Treatment-resistant Schizophrenia NCT01105481
Eligibility Treatment-resistant Schizophrenia NCT01105481
- StudyEvent: Eligibility
Similar models
Eligibility Treatment-resistant Schizophrenia NCT01105481
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
schizophrenia dsm iv
Item
dsm-iv diagnosed schizophrenic patients;
boolean
C0036341 (UMLS CUI [1,1])
C0220952 (UMLS CUI [1,2])
C0220952 (UMLS CUI [1,2])
age
Item
age between 18 and 60;
boolean
C0001779 (UMLS CUI [1])
prior therapy non-responder
Item
before treatment with clozapine, documented treatment failure of two antipsychotics for an adequate duration of 6 weeks and in a sufficient dose of 600 mg/day of chlorpromazine equivalents;
boolean
C1514463 (UMLS CUI [1,1])
C0205269 (UMLS CUI [1,2])
C0205269 (UMLS CUI [1,2])
failure to show a satisfactory clinical response to clozapine
Item
documented failure to show a satisfactory clinical response to an adequate clozapine treatment, defined as at least clozapine 300 mg/day for 3 months or a plasma drug level of 350ng/ml;
boolean
C0009079 (UMLS CUI [1,1])
C0205269 (UMLS CUI [1,2])
C0205269 (UMLS CUI [1,2])
clinical global impression, panss
Item
at least moderately ill, defined as with a clinical global impression (cgi) greater than 4 or panss total score greater than 75;
boolean
C3639708 (UMLS CUI [1,1])
C0521117 (UMLS CUI [1,2])
C0451383 (UMLS CUI [2])
C0521117 (UMLS CUI [1,2])
C0451383 (UMLS CUI [2])
positive psychotic symptoms on panss
Item
persistent positive psychotic symptoms, with rating scores of moderate or worse on at least two of four positive symptom items (delusion, conceptual disorganization, hallucinatory behavior, and suspiciousness/persecution) on positive and negative syndrome scale (panss);
boolean
C1446409 (UMLS CUI [1,1])
C0871189 (UMLS CUI [1,2])
C0439793 (UMLS CUI [1,3])
C0451383 (UMLS CUI [1,4])
C0871189 (UMLS CUI [1,2])
C0439793 (UMLS CUI [1,3])
C0451383 (UMLS CUI [1,4])
concomitant treatment with lithium, anti-convulsants, antidepressants and other antipsychotic medication ;
Item
patients with concomitant treatment with lithium, anti-convulsants, antidepressants and other antipsychotic medication ;
boolean
C1707479 (UMLS CUI [1,1])
C0023870 (UMLS CUI [1,2])
C1707479 (UMLS CUI [2,1])
C0003286 (UMLS CUI [2,2])
C1707479 (UMLS CUI [3,1])
C0003289 (UMLS CUI [3,2])
C1707479 (UMLS CUI [4,1])
C0040615 (UMLS CUI [4,2])
C0023870 (UMLS CUI [1,2])
C1707479 (UMLS CUI [2,1])
C0003286 (UMLS CUI [2,2])
C1707479 (UMLS CUI [3,1])
C0003289 (UMLS CUI [3,2])
C1707479 (UMLS CUI [4,1])
C0040615 (UMLS CUI [4,2])
severe comorbidity, cardiovascular disease, cerebrovascular disease, bone marrow suppression, epilepsy
Item
patients with underlying severe medical illness, such as cardiovascular disease, cerebrovascular disease, bone marrow suppression or epilepsy;
boolean
C0009488 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0007222 (UMLS CUI [2])
C0007820 (UMLS CUI [3])
C0280962 (UMLS CUI [4])
C0014544 (UMLS CUI [5])
C0205082 (UMLS CUI [1,2])
C0007222 (UMLS CUI [2])
C0007820 (UMLS CUI [3])
C0280962 (UMLS CUI [4])
C0014544 (UMLS CUI [5])
substance use disorder
Item
patients with comorbid diagnosis of substance dependence;
boolean
C0038586 (UMLS CUI [1])